UNSPSC 51172410: Aluminum hydroxide/magnesium hydroxide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA103. This VA Drug Class (GA103) classifies this compound as belonging to the group ALUMINUM/MAGNESIUM CONTAINING ANTACIDS.

UNSPSC 51172410 Aluminum hydroxide/magnesium hydroxide is a Commodity code that state and local procurement activity has not recently tagged with aluminum hydroxide or magnesium hydroxide purchases. The three most recent opportunities posted under this code involve offender drug testing services (Collin County Community Supervision and Corrections Department, Plano and McKinney, Texas), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products (Minnesota Multistate Cooperative Purchasing Alliance across participating states including Oregon). None of these solicitations reference the chemical compounds nominally identified by the code; the misalignment suggests that either the code assignment in the source is incorrect or state and local procurement offices are using this code to capture a broader pharmaceutical or health services category that diverges significantly from its UNSPSC definition. Recent issuing bodies include county corrections departments, state health and human services commissions, and interstate cooperative purchasing alliances administering on behalf of multiple state and local member agencies.

The three documented opportunities span Texas, Minnesota, and Oregon. The Collin County RFP (2026-327, due July 23, 2026) seeks offender specimen collection and drug testing services with an estimated contract value of $600,000 over two years, requiring immunoassay screening with LC/MS/MS or GC/MS confirmation across two collection sites. The Texas HHS Commission RFI (HHS0017013, response deadline April 3, 2026) gathered preliminary market intelligence on direct-to-manufacturer prescription programs before formal competitive bidding. The MMCAP RFP (S1070000015802, due March 26, 2026) established multiple contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers, with proposals evaluated 75 percent on price competitiveness and 25 percent on administrative compliance, fixed pricing, EDI capability, and fee agreement. The code shows minimal recent activity aligned with its chemical nomenclature; business development professionals should verify code tagging in actual solicitations before investing pursuit effort.